SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101) (PLSE) — May 7, 2020

PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101)
Date: May 7, 2020 · CIK: 0001625101 · Accession: 0001140361-20-010979

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-237577

Date
May 7, 2020
Author
By
Form
CORRESP
Company
PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101)

Letter

PULSE BIOSCIENCES, INC.

957 Point Eden Way

Hayward, California 94545

May 7, 2020

Via EDGAR

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, NE

Washington, D.C. 20549-3561

Attention:

Mr. Jeffrey Gabor

Ms. Celeste Murphy

Re:

Pulse Biosciences, Inc.

Registration Statement on Form S-3

Filed April 6, 2020

File No. 333-237577

Acceleration Request

Requested Date: May 8, 2020

Requested Time: 4:00 p.m. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pulse Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3, as amended (File No. 333-237577) (the “Registration Statement”), be declared effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Company may request by telephone to the staff of the Securities and Exchange Commission.

The Company hereby authorizes Andrew D. Hoffman of Wilson Sonsini Goodrich & Rosati, P.C., counsel for the Company, to make such request on the Company’s behalf.

The Company requests that it be notified of the effectiveness of the Registration Statement by contacting Andrew D. Hoffman at (650) 849-3240 or ahoffman@wsgr.com.

Sincerely,
PULSE BIOSCIENCES, INC.

Show Raw Text
CORRESP
1
filename1.htm

    PULSE BIOSCIENCES, INC.

    957 Point Eden Way

    Hayward, California 94545

    May 7, 2020

    Via EDGAR

    Securities and Exchange Commission

      Division of Corporation Finance

      Office of Life Sciences

      100 F Street, NE

    Washington, D.C. 20549-3561

            Attention:

            Mr. Jeffrey Gabor

            Ms. Celeste Murphy

            Re:

            Pulse Biosciences, Inc.

            Registration Statement on Form S-3

            Filed April 6, 2020

            File No. 333-237577

            Acceleration Request

            Requested Date: May 8, 2020

            Requested Time: 4:00 p.m. Eastern Time

    Ladies and Gentlemen:

    Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pulse Biosciences, Inc. (the “Company”) hereby requests that the
      above-referenced Registration Statement on Form S-3, as amended (File No. 333-237577) (the “Registration Statement”), be declared effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such
      later time as the Company may request by telephone to the staff of the Securities and Exchange Commission.

    The Company hereby authorizes Andrew D. Hoffman of Wilson Sonsini Goodrich & Rosati, P.C., counsel for the Company, to make such
      request on the Company’s behalf.

    The Company requests that it be notified of the effectiveness of the Registration Statement by contacting Andrew D. Hoffman at (650)
      849-3240 or ahoffman@wsgr.com.

            Sincerely,

            PULSE BIOSCIENCES, INC.

            By:

            /s/ Sandra A. Gardiner

            Sandra A. Gardiner

            Chief Financial Officer, Executive Vice President of Finance and Administration, Secretary and Treasurer

    cc:          Andrew D. Hoffman, Esq.,

    Wilson Sonsini Goodrich & Rosati, P.C.